Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +175.43%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.39 per share when it actually produced a loss of $0.64, delivering a surprise of -64.1%.Over the last four quarters, ...

For the quarter ended December 2025, Natera (NTRA) reported revenue of $665.5 million, up 39.8% over the same period last year. EPS came in at $0.35, compared to -$0.41 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $660.45 million, representing a surprise of +0.76%. The company delivered an EPS surprise of +175.43%, with the consensus EPS estimate being -$0.46.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

Natera (NasdaqGS:NTRA) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlexey Aleshin - General Manager of Oncology and Chief Medical OfficerCasey Woodring - VP of Equity ResearchDaniel Markowitz - VP of Equity ResearchDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Fesko - President and Chief Business OfficerMichael Brophy - CFORicki Levitus - Equity Research AssociateSolomon Moshkevich - President of Clinical DiagnosticsSteve Chapman - CEOConference Call ...

Natera (NasdaqGS:NTRA) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlexey Aleshin - General Manager of Oncology and Chief Medical OfficerCasey Woodring - VP of Equity ResearchDaniel Markowitz - VP of Equity ResearchDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Fesko - President and Chief Business OfficerMichael Brophy - CFORicki Levitus - Equity Research AssociateSolomon Moshkevich - President of Clinical DiagnosticsSteve Chapman - CEOConference Call ...

Natera (NasdaqGS:NTRA) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker10Welcome to Natera's 2025 fourth quarter financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press Star, followed by One on your touchtone phone. If anyone has difficulty hearing the conference, please press Star zero for operator assistance. As a reminder, this call is being rec ...

Natera, Inc. Q4'2025 Earnings Presentation February 26, 2026 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partnerships and potential acq ...

Group 1: Natera - Natera represents 13.2% of the Duquesne Family Office holdings, with a market cap of $28.8 billion, specializing in genetic testing for women's health, oncology, and organ health [4] - The company is currently loss-making but is projected to have revenue growth at a high-teens percentage rate over the next couple of years, with a gross profit margin increasing from 61.8% in Q3 2024 to 64.9% in Q3 2025 [4] - Natera's oncology tests grew by 54% in Q3, making up 24% of total tests, and the bullish case for the stock is supported by its Signatera personalized blood test for detecting molecular residual disease in cancer patients [5][6] Group 2: Taiwan Semiconductor Manufacturing - Taiwan Semiconductor Manufacturing represents 5.4% of the portfolio and has seen an 80% increase over the last year, driven by AI spending [8] - The company reported robust AI-related demand in 2025, while non-AI markets showed only a mild recovery, indicating a dependency on AI spending for future prospects [9] - Capital spending is projected to exceed $101 billion over the next three years due to rising costs and growth support needs, which may limit free cash flow margin expansion opportunities [10][12]

Core Insights - Natera, Inc. has launched EDEN, a large multi-center prospective study to evaluate its non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications [1] Group 1: Company Overview - Natera, Inc. is a global leader in cell-free DNA and precision medicine [1] Group 2: Industry Context - Preeclampsia affects approximately 5-8% of pregnancies and is a leading cause of maternal and neonatal morbidity [1]

Company Overview - Natera (NTRA) has submitted a premarket approval (PMA) application to the FDA for its Signatera CDx test, a personalized molecular residual disease (MRD) assay for muscle-invasive bladder cancer (MIBC) [1][6] - The PMA submission is a significant regulatory milestone for Natera, positioning Signatera CDx as a companion diagnostic to guide adjuvant immunotherapy decisions in MIBC [6][8] Clinical Data and Implications - The application is supported by positive phase 3 IMvigor011 trial data, which demonstrated improved survival outcomes in MRD-positive patients treated with Tecentriq, while MRD-negative patients showed a low risk of recurrence without additional therapy [2][9] - The trial results were strong enough to be featured in a Presidential Symposium at the ESMO Congress and published in The New England Journal of Medicine, enhancing credibility within the oncology community [10] Market Position and Growth Potential - If approved, Signatera CDx could serve as a long-term growth catalyst for Natera by expanding its MRD platform's role from monitoring to treatment decision-making [4][11] - The companion diagnostic status is expected to increase adoption among oncologists, strengthen partnerships with pharmaceutical companies, and support broader reimbursement coverage, leading to higher testing volumes and more sustainable revenue streams [4][11] Financial Performance - Natera's stock has surged 69.2% over the past six months, significantly outperforming the industry growth of 18.1% and the S&P 500's rise of 12.4% [3] - The current market capitalization of Natera stands at $31.97 billion [5] Industry Outlook - The global precision oncology market is projected to grow from an estimated $115.80 billion in 2024 to $201.96 billion by 2030, with a compound annual growth rate (CAGR) of 8.05% from 2025 to 2030 [12] - Growth in the market is driven by technological advancements, increasing demand for diagnostic solutions that provide clinically actionable insights, and the ability to reduce treatment-related side effects for cancer patients [13]

Group 1 - The tumor gene testing industry is experiencing rapid development, with significant international transactions and domestic regulatory reforms since Q4 2025 [1] - Leading U.S. tumor gene testing companies have shown strong stock price growth, with Natera, Exact Science, Guardant, and Grail achieving annual stock price increases of 52%, 78%, 221%, and 464% respectively [1] - The tumor gene testing sector maintains high growth potential, covering early screening, auxiliary diagnosis, companion diagnosis, efficacy monitoring, and recurrence prediction in precision treatment [1] Group 2 - Exact Sciences is a leading company in colorectal cancer screening, with a revenue guidance of $3.22 to $3.235 billion for 2025, representing a growth of 16.7% to 17.2% [2] - The accessible market for colorectal cancer screening in the U.S. is approximately 120 million individuals aged 45-85, with about 70 million already screened [2] - Future growth drivers for Exact Sciences include rescreening, addressing care gaps, pricing increases for Cologuard Plus, targeting younger demographics, and a strong commercialization strategy [2] Group 3 - Natera is a leader in minimal residual disease (MRD) testing, with projected revenue of approximately $2.3 billion for 2025 [3] - The core MRD product, Signatera, achieved over 200,000 samples in Q3 2025, marking a 54% year-over-year increase [3] - Natera's Signatera is one of the most scientifically validated MRD testing products, supported by over 125 peer-reviewed publications across more than 30 tumor types [3] Group 4 - The tumor gene testing industry is in a growth phase, with significant international transactions and domestic regulatory innovations [4] - Key domestic players include Adicon Biotech, which presented innovative lung cancer MRD products, and BGI Genomics, which is expanding into various cancer early screening and monitoring scenarios [4] - Mirxes-B launched China's first early screening product for gastric cancer, while Burning Rock Medical's Lungwei has achieved excellent results in multiple cancer MRD clinical trials [4]